Oxyferriscorbone elevates the total iron content of blood but not brain.
Following the intravenous infusion of oxyferriscorbone into the tail vein of the rat, the blood and brain metal ion content was measured over the following 72 h period. Administration of oxyferriscorbone increased the total iron content of blood for up to 24 h following intravenous infusion. In contrast, there was no increase in the total iron content of the cerebellum or striatum. Overall, there was no change in total zinc or copper content of the blood or brain following oxyferriscorbone administration. The effect of oxyferriscorbone in Parkinson's disease may not be related to any alteration in total iron content of the brain.
Dexter
D T
DT
University Department of Neurology, Institute of Psychiatry, London, U.K.
Jenner
P
P
Marsden
C D
CD
D015083:2,3-Diketogulonic Acid / Q000494:pharmacology*; D000496:Alloxan / Q000494:pharmacology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003300:Copper / Q000097:blood; D004338:Drug Combinations / Q000494:pharmacology; D005290:Ferric Compounds / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007501:Iron / Q000097:blood*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013400:Sugar Acids / Q000494:pharmacology*; D015032:Zinc / Q000097:blood
D004338:Drug Combinations; D005290:Ferric Compounds; D013400:Sugar Acids; D015083:2,3-Diketogulonic Acid; C008747:oxyferriscorbone; D000496:Alloxan; D003300:Copper; D007501:Iron; D015032:Zinc